GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

narlumosbart   Click here for help

GtoPdb Ligand ID: 13084

Synonyms: Jinlitai® | JMT-103 | JMT103
Approved drug
narlumosbart is an approved drug (China (2023))
Compound class: Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2023)
International Nonproprietary Names Click here for help
INN number INN
12344 narlumosbart
Synonyms Click here for help
Jinlitai® | JMT-103 | JMT103
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1357
Other databases
GtoPdb PubChem SID 491299866
Search PubMed clinical trials narlumosbart
Search PubMed titles narlumosbart
Search PubMed titles/abstracts narlumosbart